The aim of the study is to determine period and birth-cohort effects in the early initiation of phencyclidine (PCP) use in drug users in New York City (NYC). METHODS: We analyzed data collected from two surveys of street-recruited drug users in NYC. We used survival analysis and proportional hazards modeling to assess period and birth-cohort effects on risk for early initiation of PCP use. 
INTRODUCTION
The National Institute on Drug Abuse defines ''club drugs'' as ''drugs used by teens and young adults who are part of a nightclub, bar, rave, or trance scene'' (1). These drugs typically include MDMA (ecstasy), phencyclidine (PCP), gamma hydroxybutyrate, rohypnol, amphetamines, lysergic acid diethylamide (LSD), and ketamine (1, 2) . Reports suggested there may be a resurgence of club-drug use in the United States (3) (4) (5) . Drug Enforcement Agency (DEA) reports trace the beginning of this increase to the mid to late 1990s (6) . PCP has been one of the main drugs implicated in the return of club drug use (2) . PCP has been used as a recreational drug since the late 1960s, although it originally was developed for medical and surgical use as an anesthetic. It is classified as a dissociative anesthetic, but also has effects similar to such hallucinogens as LSD, such stimulants as amphetamines, and such central nervous system depressants as pentobarbital (7) . Acute or subacute PCP intoxication can cause a number of psychiatric disorders, including toxic delirium, fulminant psychosis, and depression (8) . PCP is a drug that can make users violent, delusional, paranoid, and catatonic and has gained notoriety by association with numerous homicides committed by those under its influence (9) .
Previous studies suggested that PCP use increased during the 1970s (a phase often referred to as one of ''epidemic'' PCP use) and peaked in the 1980s (10) (11) (12) . In the late 1980s, PCP went from being a drug used mainly by white adolescent males and females living in suburban areas to a drug used primarily by minority, particularly African-American, men in their 20s and 30s, centered in a handful of cities, particularly Washington, DC/Baltimore, Los Angeles, New York, St. Louis, New Orleans, and Chicago (13) (14) (15) (16) .
From January 1998 to December 2002, the Drug Abuse Warning Network of the US Department of Health and Human Services documented an increase of more than 240% in the number of emergency department visits related to PCP use, from 1,725 to 4,216. DEA seizures of the drug increased by 24% from 2000 to 2001 (17) . There was discussion in the popular media of an increase in PCP trafficking and use in New York City (NYC), particularly in residents of NYC's surrounding suburbs (18) . Emergency department visits related to PCP use in NYC increased by 67% from 2001 to 2002 (203 to 341 visits) (3) . PCP also has been implicated as one of the more common club drugs used by habitual and nonhabitual drug users. A recent study of minority substance users in northern Manhattan found club-drug use to be common (45.3% of Hispanics and 56.4% of African Americans) and PCP to be the most commonly used club drug, used at least once by 34.3% of respondents who had used club drugs (19) .
The 2002 National Survey on Drug Use and Health, conducted by the Department of Health and Human Service's Substance Abuse and Mental Health Services Administration, reported trends in PCP use, including age of initiation. This study showed that the number of new PCP users by year sharply declined from 1975 to 1982 and remained low and fairly constant from 1983 to the early 1990s. From 1993 onward, the number of new users per year began to increase again, a trend that appears to have continued (10) . The Substance Abuse and Mental Health Services Administration reported younger ages of initiation in the early 1970s (17 to 18 years old), later ages of initiation from the mid 1970s to mid 1990s (19 to 22 years old), followed by a decrease in age of initiation back to earlier levels from the mid 1990s through early 2000s (10) . These studies suggested a changing prevalence of PCP use during the last 30 years. These trends could imply a return to the earlier, more widespread pattern of PCP use seen in the United States in the late 1970s, with the concomitant concerns for public health.
A string of murders in Brooklyn and Queens in winter 2003 ultimately were blamed on PCP use, bringing the drug to the attention of several NYC communities (9) . Despite this increasing concern with PCP use, recent trends in use of the drug in NYC have been largely unexamined. Because of NYC's important place in the national portrait of drug abuse and the lack of information on changing trends in PCP use, we examined data from two surveys of habitual drug users in NYC to assess potential period and birth-cohort effects in age at first PCP use in habitual users during the past 40 years to identify changing trends in PCP use.
METHODS

Subject Recruitment
We used data from two surveys of street-recruited habitual drug users in NYC. Potential participants were recruited for two ongoing studies (19, 20) of injection drug users (IDUs) and non-IDUs (NIDUs) by using street outreach techniques described elsewhere (21, 22) .
Briefly, outreach workers engaged drug users in conversations about ongoing studies at the research storefront and places in the community where drugs were bought and/or used. Both IDUs and NIDUs were recruited between August 2000 and August 2003 from three NYC boroughs in neighborhoods with an active observable drug economy. Interviews were conducted in two storefronts in East Harlem and the South Bronx and from a recreational vehicle parked in Bedford-Stuyvesant in Brooklyn, Jamaica, Queensbridge in Queens, and the Lower East Side of Manhattan. Potential participants completed a screening demographic interview. The IDU study was designed to study correlates and predictors of hepatitis C virus infection and therefore targeted young, recently initiated IDUs at risk for hepatitis C virus infection. Participants were eligible for the IDU study if they were 15 to 40 years of age and reported injecting heroin or cocaine at least once in the last 2 months, but for no longer than 5 years. The NIDU study was designed to study correlates and predictors of transition to injection drug use. Participants were eligible for the NIDU study if they were 15 to 40 years of age and reported non-injecting drug use of heroin or cocaine at least once per week in the last 2 months, but for no longer than 10 years, and no history of injecting drug use. Only participants who currently were residents of NYC were included in this analysis.
Participants were reimbursed $20 for their participation. The institutional review board of the New York Academy of Medicine approved the study. Informed consent was obtained in writing from all study participants. Baseline data collected through March 2004 from both the IDU and NIDU studies were combined for this analysis.
Data Collection
After obtaining informed consent, eligible participants completed a standardized detailed risk-behavior questionnaire administered by trained interviewers in English or Spanish. We asked about sociodemographic characteristics, type and frequency of drug use, sexual behaviors, and sexual partnerships. The presence or absence of prior injection drug use was confirmed during the interviewing process and by phlebotomist assessment of injection stigmata (track marks). Sociodemographic characteristics included age, race, sex, education, recent homelessness, main income source, and sexual identity. We examined recent frequency of substance use in the last 2 months, focusing on the most commonly used substances, including marijuana, heroin, LSD, crack, and cocaine. Age at first use of PCP and other substances was collected through self-report.
Statistical Methods
To ensure that all study participants had an equivalent risk period for starting PCP use, we included only respondents 23 years and older in the analysis and considered risk for first PCP use by age 23. The age of 23 years was used because it was the average age of initiating PCP use plus one SD (mean age of initiating PCP Z 19 years; SD Z 4 years). By restricting the analysis to participants who were 23 years or older at the interview, all participants had the full 23-year at-risk period at the interview, and participants of all ages at the interview had equal time in which to try PCP. All survival analysis methods make an assumption that censoring is unrelated to the risk for the outcome within exposure strata; given that periods and birth cohorts were key variables of interest in this analysis, these restrictions were necessary to meet this assumption (23) .
Initially, IDUs and NIDUs were examined separately to assess differences in associations of interest in this analysis. There were no substantive differences in period and birthcohort predictors of PCP use onset between IDUs and NIDUs, and as such, the groups were combined for all analyses presented here.
We examined bivariate associations of sociodemographic factors and drug-use behaviors with PCP use by age 23 by using chi-square tests. Use of specific drugs (marijuana, cocaine, heroin, crack, and LSD) was restricted to use before the initiation of PCP use for initiators and to use before the age of 19 years for others. The age of 19 years was selected to assess prior drug use for those who did not use PCP because it is the mean age of initiating PCP use in those who initiate use, and on average, this definition will assess other drug use up to the same age for both groups, i.e., PCP use initiators and noninitiators.
We used Kaplan-Meier survival analyses to assess period and birth-cohort effects separately. Age at first PCP use was the incident time in analyses. The period survival plot was stratified by date of first use of PCP: before or after 1987, when national reports suggest that PCP use was at its lowest (10) . The birth-cohort survival plot was stratified by participant date of birth, making four separate groupings: those born between 1961 and 1965, 1966 and 1970, 1971 and 1975, and 1976 and 1980 . Differences between curves were determined by using log-rank tests.
We used proportional hazards models to determine the significance of period and birth-cohort effects when controlling for other relevant covariates. Both the period and birthcohort models were adjusted for age, sex, race/ethnicity, education, any time in a juvenile detention center, and dropping out of school. Although considering other drugs that are associated with PCP initiation is useful in describing the constellation of drugs that tend to be used by the same individuals, there is no plausible mechanism that would suggest these drugs themselves cause PCP use initiation, and as such, use of other drugs was not considered a potential confounder in multivariable models. In addition, reinforcing this approach, inclusion of prior drug use variables in proportional hazards models did not appreciably change the relations reported in this analysis. 
RESULTS
Of a total of 787 individuals from the two studies, 292 (37.1%) had used PCP by the time they were 23 years old. In this sample of drug users, 70% of participants were 27 years or older, 73% were male, 3.9% were white, 35.2% were African American, and 54.6% were Hispanic ( Table 2 ). Other variables associated with a significantly decreased risk for PCP use were age at time of interview (HR Z 0.82; 95% CI, 0.79-0.85), African-American race (HR Z 0.46; 95% CI, 0.27-0.78), and Hispanic race (HR Z 0.49; 95% CI, 0.30-0.82).
Kaplan-Meier survival curves by birth cohort, stratified by birth-year groups 1961 to 1965, 1966 to 1970, 1971 to 1975, and 1976 to 1980 , are shown in Fig. 2 . Test for equality of survival curves by birth cohort showed a significant difference (log-rank test, p Z 0.03). A second test comparing the 1971 to 1975 birth cohort with the others showed the difference to be significant (log-rank test, p ! 0.01). This figure shows that those born in the 1971 to 1975 birth cohort generally had lower risk for initiation of PCP use by age 23.
In a proportional hazards model predicting risk for PCP use by age 23, compared with those born in 1976 to 1980, those born in 1971 to 1975 had decreased risk for using PCP through age 23 (HR Z 0.58; 95% CI, 0.37-0.91; Table 3 ). Compared with white respondents, AfricanAmerican and Hispanic respondents had lower risks for using PCP (HR Z 0.38; 95% CI, 0.22-0.65 and HR Z 0.41; 
DISCUSSION
We documented period effects and birth-cohort effects on risk for early initiation of PCP use in a group of predominantly minority street-recruited drug users in NYC. Risk for PCP initiation by age 23 was greater before 1987 than after 1987. In addition, participants born during 1971 to 1975 had the lowest risk for initiating use of PCP at a given age. Positive predictors for PCP use by age 23 were white race (compared with African-American and Hispanic race) and having been in a juvenile detention center.
Our results are consistent with other observations that there has been a change over time in PCP use initiation in young people (10, 11, 13, 15) . Before 1987, a greater percentage of drug users in our cohort had used PCP by age 23 than after 1987. We also found that different birth cohorts had differing likelihoods of early initiation of use. Although the primary focus of public health interventions during the past three decades has been on prevention of adolescent and young adult initiation of PCP (15), we found that risk for early initiation of PCP use was decreasing throughout the 1970s and 1980s (15, 24) . Although we are not aware of other recent work that explicitly assessed period and birth-cohort effects on PCP use patterns, other reports provided evidence that corroborates our findings. In 1978, national reports found that average age of first use of PCP was approximately 13 years (25) . From 1976 to 1987, the number of high school seniors reporting PCP use in the prior 30 days and the number of 12-to 17-yearolds reporting ever having used PCP steadily declined (26) . From 1979 to 1982, the number of 18-to 25-yearolds reporting having used PCP declined from 14.5% to 10.5%, and concurrently, the age of emergency department patients making visits because of PCP use increased (26) . Subsequently, from 1979 to 1987, the percentage of American high school seniors reporting ever having tried PCP decreased from 12.8% to 3% (27) . This decline in use in young people seems to have continued through the late 1980s and early 1990s and is consistent with our observation of a birth-cohort effect in risk for early PCP use initiation.
It was suggested that PCP use follows cyclical trends, declining when a new generation of users experiences the drug's side effects. Other factors implicated in periodic declines in rates of use are intense public health campaigns warning of the drug's effects, targeted primarily at children and adolescents; restrictions on the purchase of pyridine (a necessary ingredient for the manufacture of PCP); and government crackdowns on production and possession of the drug, as well as movement of the drug from a DEA schedule III classification to a place on the more tightly regulated schedule II (the same schedule as cocaine) (26, 28) . In metropolitan areas, in which PCP use appears to have remained concentrated, amount of PCP use appears to be related to factors governing the consumption of ''more highly coveted'' drugs, such as crack cocaine (15) . Price and ease of acquisition of those more desirable drugs may drive PCP use trends (15) . The degree to which our results are generalizable outside NYC is unknown, and these changes in PCP use may be confined to this geographic area of study. We note that other work in the Washington, DC/Baltimore area generally found rates of PCP use to be greater than in New York and showed an increase in PCP use since the late 1990s (3). We do not know if our observations of period and birth cohorts are generalizable to other different demographic groups than those studied here. Also, period and birthcohort effects may differ between subsets of drug users. For example, persons who predominantly buy and use PCP on the street may be different than those who predominantly buy and use PCP in clubs. However, we note that our findings highlight the more general phenomenon of a particular drug's rise and fall over time. This may be important to consider in the context of drug use surveillance and prediction.
Although PCP and methamphetamines are often considered club drugs, they also often are sold in the streets (5, 19) . We do not have information on this to assess whether PCP use was within a club or in another context. Recent reports suggested that club drugs are being purchased increasingly on the street, something that would need to be considered in basing interventions on these findings (29, 30) . This study focuses on habitual drug users. It is possible that more casual recreational users make up the bulk of the increase in PCP use seen in the past decade, and that these users follow different age and demographic patterns than those documented here. Our sample is predominantly male. It was suggested that female PCP users are different in their reasons for initiating and continuing to use PCP (6) , and as such, our results must be generalized with caution to populations with different demographic composition.
Notwithstanding these limitations, our data suggest a changing likelihood of PCP use by a given age during different periods and among different birth cohorts of habitual drug users in NYC during the past 30 years. Those who initiated PCP use after 1987, when PCP popularity was at its nadir, were less likely to have initiated PCP use by age 23 than those who initiated use before 1987. Understanding secular trends in club-drug use patterns is essential for designing effective risk-reduction interventions and to identify likely patterns in cohorts at risk for using these drugs in the future. Period and birth-cohort effects may be present in the use of other drugs over time; understanding such patterns may be important for efforts aimed at surveillance, prediction, and minimizing use of illicit drugs.
